GondolaBio is a collection of biopharmaceutical companies focused on developing next‑generation therapeutics for genetic diseases. Originally carved out of BridgeBio, GondolaBio secured $300M in private financing from external investors in 2024 and became an independent company within the BridgeBio ecosystem. GondolaBio aims to leverage cutting‑edge biological research to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases.
One of GondolaBio’s subsidiaries is an early preclinical stage biotechnology company developing a novel best‑in‑class therapeutic for a rare, severe genetic disease, advancing toward first‑in‑human clinical studies.
GondolaBio is a collection of biopharmaceutical companies focused on developing next‑generation therapeutics for genetic diseases. Originally carved out of BridgeBio, GondolaBio secured $300M in private fina...